Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports
AIM: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have gained significant importance in the treatment of type 2 diabetes mellitus. One of the adverse effects while using SGLT-2 inhibitors is euglycemic ketoacidosis (euDKA) - acute life-threatening emergency. METHODS: The following review of ca...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Format: | Book |
Published: |
Kazimierz Wielki University,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | AIM: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have gained significant importance in the treatment of type 2 diabetes mellitus. One of the adverse effects while using SGLT-2 inhibitors is euglycemic ketoacidosis (euDKA) - acute life-threatening emergency. METHODS: The following review of case reports was based on articles published in 2023, obtained from the PubMed databases. Key search terms included "case report", "sglt-2", "sglt-2i", "sodium-glucose cotransporter inhibitors", "dka". "eudka", "euglycemic ketoacidosis". RESULTS: In the literature, cases of euDKA correlated with the use of SGLT-2 inhibitors are described. CONCLUSION: There is a need for greater observation of the frequency of the adverse effects in patients taking sodium-glucose cotransporter inhibitors (SGLT-2i) and for raising awareness among doctors about the possibility of developing euglycemic diabetic ketoacidosis during the SGLT-2 inhibitors therapy. |
---|---|
Item Description: | 10.12775/JEHS.2024.68.55325 2391-8306 |